Literature DB >> 22879081

Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer.

Wouter van Elmpt1, Michel Ollers, Anne-Marie C Dingemans, Philippe Lambin, Dirk De Ruysscher.   

Abstract

UNLABELLED: This study investigated the possibility of early response assessment based on (18)F-FDG uptake during radiotherapy with respect to overall survival in patients with non-small cell lung cancer.
METHODS: (18)F-FDG PET/CT was performed before radiotherapy and was repeated in the second week of radiotherapy for 34 consecutive lung cancer patients. The CT volume and standardized uptake value (SUV) parameters of the primary tumor were quantified at both time points. Changes in volume and SUV parameters correlated with 2-y overall survival.
RESULTS: The average change in mean SUV in the primary tumor of patients with a 2-y survival was a decrease by 20% ± 21%-significantly different (P < 0.007) from nonsurvivors, who had an increase by 2% ± 22%. A sensitivity and specificity of 63% and 93%, respectively, to separate the 2 groups was reached for a decrease in mean SUV of 15%. Survival curves were significantly different using this cutoff (P = 0.001). The hazard ratio for a 1% decrease in mean SUV was 1.032 (95% confidence interval, 1.010-1.055). Changes in tumor volume defined on CT did not correlate with overall survival.
CONCLUSION: The use of repeated (18)F-FDG PET to assess treatment response early during radiotherapy is possible in patients undergoing radiotherapy or sequential or concurrent chemoradiotherapy. A decrease in (18)F-FDG uptake by the primary tumor correlates with higher long-term overall survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22879081      PMCID: PMC4667805          DOI: 10.2967/jnumed.111.102566

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  36 in total

1.  The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer.

Authors:  Philippe Lambin; Steven F Petit; Hugo J W L Aerts; Wouter J C van Elmpt; Cary J G Oberije; Maud H W Starmans; Ruud G P M van Stiphout; Guus A M S van Dongen; Kristoff Muylle; Patrick Flamen; André L A J Dekker; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2010-07-19       Impact factor: 6.280

2.  Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.

Authors:  Dae Ho Lee; Seok-Ki Kim; Ho-Young Lee; Sung Young Lee; Sun Hwa Park; Hyae Young Kim; Keon Wook Kang; Ji-Youn Han; Heung Tae Kim; Jin Soo Lee
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

3.  Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer.

Authors:  Jana Fox; Eric Ford; Kristin Redmond; Jessica Zhou; John Wong; Danny Y Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-27       Impact factor: 7.038

4.  A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET.

Authors:  Mathieu Hatt; Catherine Cheze le Rest; Alexandre Turzo; Christian Roux; Dimitris Visvikis
Journal:  IEEE Trans Med Imaging       Date:  2009-01-13       Impact factor: 10.048

5.  Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer.

Authors:  Angela van Baardwijk; Stofferinus Wanders; Liesbeth Boersma; Jacques Borger; Michel Ollers; Anne-Marie C Dingemans; Gerben Bootsma; Wiel Geraedts; Cordula Pitz; Ragnar Lunde; Philippe Lambin; Dirk De Ruysscher
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

7.  Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.

Authors:  Hugo J W L Aerts; Angela A W van Baardwijk; Steven F Petit; Claudia Offermann; Judith van Loon; Ruud Houben; Anne-Marie C Dingemans; Rinus Wanders; Liesbeth Boersma; Jacques Borger; Gerben Bootsma; Wiel Geraedts; Cordula Pitz; Jean Simons; Bradly G Wouters; Michel Oellers; Philippe Lambin; Geert Bosmans; Andre L A J Dekker; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2009-03-28       Impact factor: 6.280

8.  Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial.

Authors:  Femke O B Spoelstra; Jason R Pantarotto; John R van Sörnsen de Koste; Ben J Slotman; Suresh Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-26       Impact factor: 7.038

9.  Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?

Authors:  Andrij Abramyuk; Sergey Tokalov; Klaus Zöphel; Arne Koch; Kornelia Szluha Lazanyi; Charles Gillham; Thomas Herrmann; Nasreddin Abolmaali
Journal:  Radiother Oncol       Date:  2009-01-23       Impact factor: 6.280

10.  Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.

Authors:  Mary Feng; Feng-Ming Kong; Milton Gross; Shaneli Fernando; James A Hayman; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-15       Impact factor: 7.038

View more
  43 in total

Review 1.  Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Marco Das; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  A radiobiological model of radiotherapy response and its correlation with prognostic imaging variables.

Authors:  Mireia Crispin-Ortuzar; Jeho Jeong; Andrew N Fontanella; Joseph O Deasy
Journal:  Phys Med Biol       Date:  2017-01-31       Impact factor: 3.609

3.  Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.

Authors:  Dietmar Tamandl; Richard M Gore; Barbara Fueger; Patrick Kinsperger; Michael Hejna; Matthias Paireder; Alexander Haug; Sebastian F Schoppmann; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2015-06-05       Impact factor: 5.315

4.  FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).

Authors:  Pierre Vera; Sandrine Mezzani-Saillard; Agathe Edet-Sanson; Jean-François Ménard; Romain Modzelewski; Sebastien Thureau; Marc-Etienne Meyer; Khadija Jalali; Stéphane Bardet; Delphine Lerouge; Claire Houzard; Françoise Mornex; Pierre Olivier; Guillaume Faure; Caroline Rousseau; Marc-André Mahé; Philippe Gomez; Isabelle Brenot-Rossi; Naji Salem; Bernard Dubray
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

Review 5.  Predicting outcomes in radiation oncology--multifactorial decision support systems.

Authors:  Philippe Lambin; Ruud G P M van Stiphout; Maud H W Starmans; Emmanuel Rios-Velazquez; Georgi Nalbantov; Hugo J W L Aerts; Erik Roelofs; Wouter van Elmpt; Paul C Boutros; Pierluigi Granone; Vincenzo Valentini; Adrian C Begg; Dirk De Ruysscher; Andre Dekker
Journal:  Nat Rev Clin Oncol       Date:  2012-11-20       Impact factor: 66.675

Review 6.  Positron emission tomography/computerized tomography in lung cancer.

Authors:  Ilgin Sahiner; Gulin Ucmak Vural
Journal:  Quant Imaging Med Surg       Date:  2014-06

7.  Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.

Authors:  Jillian Maclean; Matthew Aldridge; Jamshed Bomanji; Susan Short; Naomi Fersht
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

8.  Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Authors:  Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

9.  Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability.

Authors:  Ralph T H Leijenaar; Sara Carvalho; Emmanuel Rios Velazquez; Wouter J C van Elmpt; Chintan Parmar; Otto S Hoekstra; Corneline J Hoekstra; Ronald Boellaard; André L A J Dekker; Robert J Gillies; Hugo J W L Aerts; Philippe Lambin
Journal:  Acta Oncol       Date:  2013-09-09       Impact factor: 4.089

10.  Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.

Authors:  Olarn Roengvoraphoj; Cherylina Wijaya; Chukwuka Eze; Minglun Li; Maurice Dantes; Julian Taugner; Amanda Tufman; Rudolf Maria Huber; Claus Belka; Farkhad Manapov
Journal:  Strahlenther Onkol       Date:  2017-11-07       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.